IN2014DN03054A - - Google Patents

Info

Publication number
IN2014DN03054A
IN2014DN03054A IN3054DEN2014A IN2014DN03054A IN 2014DN03054 A IN2014DN03054 A IN 2014DN03054A IN 3054DEN2014 A IN3054DEN2014 A IN 3054DEN2014A IN 2014DN03054 A IN2014DN03054 A IN 2014DN03054A
Authority
IN
India
Prior art keywords
hpv
vlp
chimaeric
relates
prophylaxis
Prior art date
Application number
Other languages
English (en)
Inventor
Edward Peter Rybicki
Inga Isabel Hitzeroth
Original Assignee
Univ Cape Town
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cape Town filed Critical Univ Cape Town
Publication of IN2014DN03054A publication Critical patent/IN2014DN03054A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/295Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01DNA viruses
    • C07K14/025Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04Inactivation or attenuation; Producing viral sub-units
    • C12N7/045Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20023Virus like particles [VLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IN3054DEN2014 2011-12-01 2012-12-03 IN2014DN03054A (OSRAM)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA201108841 2011-12-01
PCT/IB2012/056912 WO2013080187A1 (en) 2011-12-01 2012-12-03 Hpv chimaeric particle

Publications (1)

Publication Number Publication Date
IN2014DN03054A true IN2014DN03054A (OSRAM) 2015-05-15

Family

ID=48534756

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3054DEN2014 IN2014DN03054A (OSRAM) 2011-12-01 2012-12-03

Country Status (18)

Country Link
US (1) US9771397B2 (OSRAM)
EP (1) EP2785842A4 (OSRAM)
JP (1) JP6228922B2 (OSRAM)
KR (1) KR102013801B1 (OSRAM)
CN (1) CN103890177B (OSRAM)
AU (1) AU2012345443B2 (OSRAM)
BR (1) BR112014012491A2 (OSRAM)
CA (1) CA2850293C (OSRAM)
HK (1) HK1198703A1 (OSRAM)
IL (1) IL232584B (OSRAM)
IN (1) IN2014DN03054A (OSRAM)
MX (1) MX355352B (OSRAM)
MY (1) MY184076A (OSRAM)
PH (1) PH12014500466A1 (OSRAM)
RU (1) RU2642287C2 (OSRAM)
SG (1) SG11201401579UA (OSRAM)
WO (1) WO2013080187A1 (OSRAM)
ZA (1) ZA201403557B (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2419143B8 (en) 2009-04-13 2018-06-27 INSERM - Institut National de la Santé et de la Recherche Médicale Hpv particles and uses thereof
WO2013119877A1 (en) 2012-02-07 2013-08-15 Aura Biosciences, Inc. Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
KR102257009B1 (ko) 2013-09-18 2021-05-27 아우라 바이오사시언시스, 인크. 종양의 진단 및 치료를 위한 바이러스-유사 입자 접합체
CN104531741B (zh) * 2014-08-22 2016-08-24 天津康希诺生物技术有限公司 增强hpv抗原表位肽免疫原性的方法及类病毒颗粒、颗粒制备方法与应用
CN105801704B (zh) * 2014-12-31 2020-06-02 艾托金生物医药(苏州)有限公司 一种具有抗宫颈癌细胞活性的重组疫苗构建方法及应用
AU2016308286B2 (en) 2015-08-18 2022-04-07 Rakuten Medical, Inc. Phthalocyanine dye conjugates and their storage
ES2992591T3 (en) 2015-08-18 2024-12-16 Rakuten Medical Inc Compositions, combinations and related methods for photoimmunotherapy
MX2018005468A (es) 2015-10-30 2018-11-09 The Us Secretary Department Of Health And Man Services Terapia dirigida contra el cáncer.
CN110650750A (zh) 2017-04-04 2020-01-03 阿维迪科技公司 基于肽的疫苗、其制造方法及其用于诱导免疫应答的用途
BR112019027488A2 (pt) 2017-06-23 2020-07-07 Pathovax Llc partículas semelhantes a vírus quiméricas e usos destas como redirecionadores de respostas imunológicas antígeno-específicos
CN113396155A (zh) 2018-12-27 2021-09-14 维伊木恩股份有限公司 偶联病毒样颗粒及其作为抗肿瘤免疫重定向剂的用途
WO2021161179A1 (en) * 2020-02-10 2021-08-19 University Of Cape Town Plant produced bovine papillomavirus virus-like particles and pseudovirions
JP2023552040A (ja) 2020-10-19 2023-12-14 ヴェリミューン インコーポレイテッド ウイルスにインスパイアされた組成物及びがんの治療のために同じものを使用して、既存の免疫応答をリダイレクトする方法
KR102821363B1 (ko) 2023-02-06 2025-06-13 영산대학교산학협력단 드론에 장착된 라이다 센서를 기초로 하는 수심 측량 시스템

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2264126T3 (es) * 1994-05-16 2006-12-16 MERCK & CO., INC. Vacunas contra el papilomavirus.
SI1105466T1 (sl) * 1998-08-14 2006-08-31 Merck & Co Inc Postopek za ciscenje virusu podobnih delcev humanega papilomskega virusa
US20020016372A1 (en) * 2000-07-31 2002-02-07 Allison Anthony Clifford Method for preventing and treating alzheimer's disease and brain damage associated with cardiov ascular disease and head injury
AU2003213065A1 (en) 2002-02-14 2003-09-04 Novavax, Inc. Novel insect cell line
PT1506222E (pt) * 2002-05-17 2009-06-12 Univ Cape Town Proteínas l1 quiméricas do papilomavírus humano 16 incluindo um péptido l2, partículas semelhantes a vírus preparadas a partir daquelas e um método de preparação das partículas
CN101166827B (zh) 2005-04-29 2013-09-04 开普敦大学 在植物中表达蛋白质
CN107080833A (zh) * 2009-04-10 2017-08-22 约翰·霍普金斯大学 作为广谱人类乳头状瘤病毒(hpv)疫苗的乳头状瘤病毒样颗粒(vlp)
WO2010147268A1 (ko) * 2009-06-19 2010-12-23 아이진 주식회사 자궁경부암 백신
WO2010149752A2 (en) 2009-06-25 2010-12-29 Glaxosmithline Biologicals S.A. Novel compositions
WO2011077371A1 (en) * 2009-12-22 2011-06-30 University Of Cape Town Method for enhancing the expression of hpv l1

Also Published As

Publication number Publication date
AU2012345443A1 (en) 2014-04-17
SG11201401579UA (en) 2014-07-30
BR112014012491A2 (pt) 2017-06-06
RU2642287C2 (ru) 2018-01-24
MY184076A (en) 2021-03-17
CN103890177B (zh) 2016-03-09
CA2850293A1 (en) 2013-06-06
US20140377367A1 (en) 2014-12-25
CN103890177A (zh) 2014-06-25
AU2012345443B2 (en) 2017-10-26
RU2014126587A (ru) 2016-01-27
EP2785842A1 (en) 2014-10-08
MX2014006520A (es) 2014-11-21
IL232584A0 (en) 2014-06-30
NZ622595A (en) 2016-04-29
JP6228922B2 (ja) 2017-11-08
MX355352B (es) 2018-04-17
KR102013801B1 (ko) 2019-08-23
HK1198703A1 (en) 2015-05-29
JP2015500229A (ja) 2015-01-05
CA2850293C (en) 2019-10-08
KR20140098061A (ko) 2014-08-07
EP2785842A4 (en) 2015-11-25
ZA201403557B (en) 2020-10-28
US9771397B2 (en) 2017-09-26
PH12014500466A1 (en) 2022-05-11
IL232584B (en) 2018-10-31
WO2013080187A1 (en) 2013-06-06

Similar Documents

Publication Publication Date Title
MY184076A (en) Hpv chimaeric particle
MX2023014569A (es) Anticuerpos anti-sirpa.
PH12019502269A1 (en) Quinazoline derivatives for the treatment of viral infections and further diseases
MX2022007522A (es) Anticuerpos anti-cd27.
HK1246183A1 (zh) Hpv疫苗
PH12017500296A1 (en) Anti-tigit antibodies
MA40458A (fr) Méthodes de traitement du cancer du col de l'utérus
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
MX361218B (es) Análogos de spliceostatina.
EA032929B1 (ru) Нейтрализующее вирус иммунодефицита человека антитело и способы его применения
PH12015500713B1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
PH12014500724A1 (en) Substituted aminothiazoles as inhibitors of cancers, including hepatocellular carcinoma, and as inhibitors of hepatitis virus replication
MX343505B (es) Metodos y composiciones para inhibir la transmision del vih.
WO2015054678A3 (en) Human papilloma virus therapeutic vaccine
EP2978449A4 (en) Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
EP3010507A4 (en) Compositions and methods for potentiating immune response for the treatment of infectious diseases and cancer
EP2601967A4 (en) MEDICINE FOR PREVENTING AND TREATING HIV-RELATED OR HIV-RELATED DISEASES, INCLUDING AIDS
IN2011CH03893A (OSRAM)
PH12017500928A1 (en) A rabies composition comprising pika adjuvant
WO2013093629A3 (en) Modular vaccines, methods and compositions related thereto
IN2014DN10683A (OSRAM)
WO2011054996A3 (es) Vacunas para el tratamiento de neoplasias a partir de capsides virales de birnavirus conteniendo antigenos del virus del papiloma humano
UA90646C2 (ru) Способ лечения часто рецидивирующей хронической герпетической инфекции, вызванной вирусом герпеса простого и и ии типов
UA59657U (ru) Способ лечения женщин с фоновыми заболеваниями шейки матки на фоне генитальной герпесвирусной инфекции